[Prophylactic intravesical chemotherapy in bladder tumors after surgery of upper tract urothelial carcinoma].
Sixteen patients with upper tract urothelial carcinoma underwent intravesical chemotherapy usually at 2 week intervals in the first year and at 4 week intervals in the second year after nephrouretectomy. For bladder instillation 10 mg mitomycin C in 20 ml saline was used on 7 patients, 5 mg carboquone and 100 mg cytosine arabinoside in 40 ml saline on 5 patients and 30 mg adriamycin in 40 ml saline on 4 patients. Two (12.5%) of the 16 patients developed bladder tumors within 2 years after surgery, but 11 (42.3%) of the 26 patients with upper tract urothelial carcinoma who did not receive intravesical chemotherapy suffered from bladder tumor within 2 years after surgery. Prophylactic intravesical chemotherapy reduced significantly (p less than 0.1) the incidence of bladder tumor after the surgery of renal pelvic and ureteral tumors.
D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002225:Carbazilquinone / Q000008:administration & dosage; D002295:Carcinoma, Transitional Cell / Q000601:surgery*; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009392:Nephrectomy; D011184:Postoperative Period; D014513:Ureter / Q000601:surgery; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control*; D014571:Urologic Neoplasms / Q000601:surgery*
D008937:Mitomycins; D003561:Cytarabine; D002225:Carbazilquinone; D016685:Mitomycin; D004317:Doxorubicin